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Objective: To evaluate the prognostic role of both
interim fluorine-18 fludeoxyglucose positron emission
tomography (i-18F-FDG-PET) and end-of-chemotherapy
fluorine-18 fludeoxyglucose positron emission tomogra-
phy (eoc-18F-FDG-PET) in patients with early-stage
Hodgkin lymphoma (HL).
Methods: We screened 257 patients with early-stage HL
treated with combined modality therapy between March
2003 and July 2011. All were staged using fluorine-18
fludeoxyglucose positron emission tomography (18F-FDG-
PET) before chemotherapy and after two doxorubicin,
bleomycin, vinblastine and dacarbazine cycles (i-18F-FDG-
PET); 165 patients were also evaluated by 18F-FDG-PET at
the end of chemotherapy (eoc-18F-FDG-PET).
Results: After revision, 85% of patients were negative for
i-18F-FDG-PET and 15% were positive. After eoc-18F-FDG-
PET revision, 23 patients had a positive scan. The median
follow-up was 56 months. The 5-year overall survival (OS)
and progression-free survival (PFS) for the whole cohort
were 97.5% and 95.6%, respectively. For i-18F-FDG-
PET-negative and i-18F-FDG-PET-positive patients, the
5-year PFS rates were 98% and 84%, respectively; for
eoc-18F-FDG-PET-negative and eoc-18F-FDG-PET-positive
patients, the 5-year PFS rates were 97% and 78%, re-
spectively. Combining the i-18F-FDG-PET and eoc-18F-FDG-
PET results, the 5-year PFS were 97%, 100% and 82% in
negative/negative, positive/negative and positive/positive
groups, respectively. The 5-year OS rates were 98% and 83%
in eoc-18F-FDG-PET-negative and eoc-18F-FDG-PET-positive
patients, respectively; the 5-year OS was 98%, 100% and
83% in negative/negative, positive/negative and positive/
positive groups, respectively.
Conclusion: This study provides additional information
on the prognostic role of i-18F-FDG-PET and eoc-18F-
FDG-PET in early-stage HL. As data are accumulating and
the clinical scenario is rapidly evolving, we might need to
rethink the use of 18F-FDG-PET as a prognostic marker for
early-stage HL in the near future.
Advances in knowledge: This study provides additional
information on the prognostic role of i-18F-FDG-PET and
eoc-18F-FDG-PET in early-stage HL. On the basis of the
present data, we may suggest to use eoc-18F-FDG-PET as
a strong prognostic marker, especially for patients with
i-18F-FDG-PET positivity.
INTRODUCTION
The combination of brief chemotherapy and radiotherapy
(RT) has shown excellent results in early-stage Hodgkin
lymphoma (HL), with cure rates .90%.1 As the risk of late
treatment-related toxicity is still a matter of debate, over
the past two decades, a great effort has been made to tailor
treatment strategies on the basis of prognostic factors.
Studies on advanced stages of HL showed that early interim
fluorine-18 fludeoxyglucose positron emission tomography
(i-18F-FDG-PET) is the most powerful tool to predict clin-
ical outcome.2–4 Recent retrospective data suggest that i-18F-
FDG-PET is prognostic also for patients with early-stage
HL undergoing combined modality therapy.5–8 In two large
co-operative positron emission tomography (PET)-response–
adapted prospective trials,9,10 i-18F-FDG-PET negative-predictive
value reached 90%. Although the evidence in favour of the
use of i-18F-FDG-PET in early stages is increasing, the role of
fluorine-18 fludeoxyglucose positron emission tomography
(18F-FDG-PET) at the end of chemotherapy (eoc) before RT
[i.e. after four doxorubicin, bleomycin, vinblastine and dacar-
bazine (ABVD) cycles in most cases] has been poorly in-
vestigated. Preliminary studies on eoc-18F-FDG-PET reported
a negative-predictive value for 2-year progression-free survival
(PFS) of 94–100% for patients who received ABVD,11,12 with
a positive-predictive value of 91–92%. Interestingly, Barnes
et al12 in retrospective series of 96 patients found no difference
in PFS according to i-18F-FDG-PET, whereas eoc-18F-FDG-
PET resulted a strong prognostic factor. The ability of both
i-18F-FDG-PET and eoc-18F-FDG-PET to predict prognosis is,
however, influenced by multiple factors, including (a) timing
in relation to chemotherapy, (b) image interpretation, (c)
disease stage, (d) bulky disease, (e) chemotherapy scheme and
(f) radiation therapy administration. In order to reduce the
risk of misinterpretation, the 2007 International Harmoniza-
tion Project criteria, the 5-point Deauville criteria, the Lugano
classification and the 2015 recommendations of the International
Conference on Malignant Lymphoma imaging and clinical working
groups reset the rules for response evaluation.13–15 The in-
terpretation key proposed by International Conference on
Malignant Lymphoma for both interim and end-of-treatment
PET is the Deauville 5-point scale, using the classic visual
assessment.15,16 A previous collaborative study was able to
show that the majority of patients with a positive i-18F-FDG-
PET after two ABVD cycles (Deauville scores 4–5) can still be
cured by the continuation of chemotherapy followed by
radiation.6
The aim of the present study was to analyse a group of
patients with early-stage HL treated with combined modality
that had both i-18F-FDG-PET and eoc-18F-FDG-PET infor-
mation, allowing for a comparison of outcomes and prog-
nostic role.
METHODS AND MATERIALS
In this multicentre retrospective study, we reviewed medical
records of patients affected with early-stage HL diagnosed be-
tween March 2003 and July 2011, all treated with combined
modality therapy in four haematology/radiation oncology
departments. Full outcome data and i-18F-FDG-PET results of
this population were already reported.6 For the present report,
we retrieved patients who had both i-18F-FDG-PET (after two
cycles, immediately before the third cycle) and eoc-18F-FDG-
PET scans. All patients had biopsy-proven early-stage HL, clas-
sified as favourable and unfavourable according to the European
Organisation for Research and Treatment of Cancer (EORTC)
criteria, and were treated with an intention-to-treat chemo-
radiation programme, with 3–4 cycles of ABVD followed by
involved field RT. All patients started chemotherapy with ABVD;
the number of cycles and any subsequent chemotherapy mod-
ification, after both i-18F-FDG-PET and eoc-18F-FDG-PET, were
at the discretion of the treating physicians; all patients received
consolidation RT limited to the initial sites of disease pre-
sentation; and the radiation dose ranged between 20 and 40Gy
delivered in 1.8 or 2 Gy daily fractions, at the discretion of the
treating radiation oncologist. Bulky disease was defined
Table 1. Baseline demographic and clinical characteristics
Characteristics n %
Total number 165 100



































ABVD, adryamicin, bleomycin, vinblastine and dacarbazine; PET,
positron emission tomography; RT, radiotherapy.
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according to the European Organisation for Research and Treat-
ment of Cancer criteria. All 18F-FDG-PET scans (i-18F-FDG-PET
and eoc-18F-FDG-PET) were reviewed by local nuclear medicine
physicians, blinded for clinical outcome, and independently re-
interpreted according to the Deauville 5-point scoring system.
Positive scans (PET1) were defined by a Deauville score $4 (i.e.
uptake moderately more than liver uptake). The institutional re-
view boards approved the study.
Statistical considerations
Categorical variables were reported as absolute and percentage
frequency. To verify a change between the paired-data, i-18F-
FDG-PET and final 18F-FDG-PET, the McNemar test was used.
The ability to predict the final 18F-FDG-PET status from i-18F-
FDG-PET was expressed as sensitivity (true-positive rate, pro-
portion of final PET positive correctly identified from positive
interim PET) and specificity (true-negative rate, proportion of
negative final PET correctly identified from negative interim
PET). PFS was defined at the time from the date of diagnosis to
the date of last observation, progression, relapse or death from
any cause. Overall survival (OS) was defined from the date of
diagnosis to the date of last follow-up or death from any cause.
Survival estimates were calculated using the Kaplan–Meier
method, and the log-rank test was used to compare survival
between different cohorts. Cox proportional hazard regression
model was used to perform univariate and multivariate analyses.
The effect of covariates was reported as hazard ratio (HR), with
confidence interval at 95% (95% CI).
RESULTS
eoc-18F-FDG-PET and i-18F-FDG-PET information were avail-
able for 165 out of 257 screened patients. Pre-treatment and
treatment characteristics of the whole cohort are described in
detail in Table 1. After revision, 140 patients were i-18F-FDG-
PET negative (Deauville scores 1–3), and 25 were i-18F-FDG-
PET positive (Deauville scores 4–5). Among patients with
a negative i-18F-FDG-PET scan, 138 continued with ABVD
chemotherapy (4 total cycles) and only 2 patients received dif-
ferent chemotherapy regimens. Among positive patients, 3 were
shifted to other chemotherapy regimens (DHAP, BEACOPP and
MINE) plus RT, whereas 22 continued with ABVD and RT. After
eoc-18F-FDG-PET revision, 23 patients had a positive scan
(19 were also positive at i-18F-FDG-PET and 4 changed from
negative to positive). Table 2 describes the concordance between
i-18F-FDG-PET and eoc-18F-FDG-PET. Four patients turned out
to be positive while being negative at interim scan, three with
a Deauville score of 4 and one with a Deauville score of 5.
Figure 1 describes in detail 18F-FDG-PET results and treatments
received for the whole cohort.
Patients were treated with a large RT dose spectrum. 42/165
(25.4%) patients received a total dose of $36Gy and the
remaining 123 (74.6%) received a total dose of ,36Gy. In the
eoc-PET-positive group, 18 patients (18/23, 78%) received
$36Gy, while the remaining 5 patients received 30Gy; all 3
relapsed patients received a total dose of $36Gy.
After a median follow-up of 56 months (range 9–163 months),
158 patients were alive without evidence of disease, 1 alive with
disease and 6 dead (4 due to disease and 2 due to other causes).
Three out of four lymphoma-related deaths occurred in
eoc-18F-FDG-PET-positive patients. Among the eoc-18F-FDG-
PET-negative patients, three relapses occurred: one died of
progressive disease and two obtained a second complete re-
mission after salvage high-dose chemotherapy and autologous
transplantation. The 5-year OS and disease-specific survival rate
was 97.5% and 98.3%, respectively; 7 out of 165 (4.2%) patients
had disease relapse/progression and the 5-year PFS for the whole
cohort was 95.6%.
For i-18F-FDG-PET-negative and i-18F-FDG-PET-positive patients,
the 5-year PFS rates were 98% and 84%, respectively (p50.0014);
for eoc-18F-FDG-PET-negative and eoc-18F-FDG-PET-positive
patients, the 5-year PFS rates were 97% and 78%, respectively
(p, 0.0001). Combining interim and eoc results, the 5-year
PFS rate was 97%, 100% and 82% in negative/negative,
positive/negative and positive/positive groups, respectively
(p, 0.0001). The 5-years OS rates were 98% and 83% in
eoc-18F-FDG-PET negative and positive patients (p5 0.0001),
respectively; 5-years OS was 98%, 100% and 83% in negative/
negative, positive/negative and positive/positive groups, re-
spectively (p, 0.00001). The Kaplan–Meier graphs displaying
these findings are shown in Figures 1 and 2.
69 patients (69/165, 42%) had bulky disease at presentation;
58/69 (84%) were i-18F-FDG-PET negative (Deauville scores
1–3) and 11/69 (16%) were i-18F-FDG-PET positive (Deauville
scores 4–5). After eoc-18F-FDG-PET revision, 10 patients were
positive at scan (9 were also positive at i-18F-FDG-PET and
1 changed from negative to positive). In 3 out of 69 (4%)
patients, the eoc-18F-FDG-PET result was changed and in 66/69
(96%) was unchanged. The correlation between i-18F-FDG-PET
and eoc-18F-FDG-PET in bulky disease was 0.83 (Spearman’s
test of correlation p, 0.0001). Among patients with bulky dis-
ease, 5-year disease-free survival (DFS) and OS were 98% (95%
CI 88–100%) and 60% (95% CI 25–83%) (p, 0.0001), and
98% (95% CI 88–100%) and 70% (95% CI 33–89%)
(p5 0.0002) for eoc-18F-PET-negative and eoc-18F-PET-positive
patients, respectively (Figure 3).
Table 2. Distribution of interim fluorine-18 fludeoxyglucose
positron emission tomography (i-18F-FDG-PET) and end-of-








Negative (2) 136 (96) 4 (17) 140 (85)
Positive (1) 6 (4) 19 (83) 25 (15)
Total 142 23 165
Spearman test of correlation: 0.76 (p,0.0001). 4/140 (2.8%) change
from i-18F-FDG-PET negative to eoc-18F-FDG-PET positive; 6/25 (24%)
change from i-18F-FDG-PET positive to eoc-18F-FDG-PET negative;
155/165 (94%) unchanged. McNemar’s exact test, p50.754. Sensitivity,
83%; specificity, 96%; receiver–operating characteristic area, 89%;
positive-predictive value, 76%; negative-predictive value, 97%.
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At univariate analysis, B symptoms (p5 0.035), positive i-18F-
FDG-PET (p5 0.014) and positive eoc-18F-FDG-PET (0.0001)
resulted being associated with a worse OS; the same factors were
associated with worse PFS (B symptoms p5 0.0114; positive
i-18F-FDG-PET p, 0.0001; eoc-18F-FDG-PET p, 0.0001). Cox
regression analysis adjusted by age, B-symptoms, stage, histology
and chemotherapy cycles showed that positive eoc-18F-FDG-
PETwas the only significant predictor of disease recurrence (HR
8.30, 95% CI 1.87–36.9, p5 0.001) and worse OS (HR 11.9,
95% CI 2.07–68.2, p5 0.005). Comparing i-18F-FDG-PET and
eoc-18F-FDG-PET results in terms of predictive value on PFS,
a significant difference was detected, with integrated area under
the curve (AUC) of 0.685 and 0.872 for i-18F-FDG-PET and
eoc-18F-FDG-PET, respectively (Wilcoxon test, p5 0.003).
DISCUSSION
In this observational study, we aimed to explore the potential
prognostic value of eoc-18F-FDG-PET in addition to early i-18F-
FDG-PET in a cohort of 165 patients with early-stage HL who
were treated with combined modality therapy. Our findings
should be interpreted in light of previous observations on the
prognostic role of i-18F-FDG-PET in early-stage HL.5–9 The
retrospective nature, the limited number of events and the ab-
sence of a centralized PET review represent the major limitations
of our study. However, the use of the Deauville score system
limited the interobserver variability in imaging interpretation,
and local nuclear medicine physicians performed a blin-
ded review.
Moreover, we here provide novel findings on the combination of
metabolic information obtained at different time points. To date,
i-18F-FDG-PET is frequently used as a prognostic tool in
patients treated with ABVD plus RT outside clinical trials.
However, the use of this prognostic information is still a matter
of debate. In the context of a more conservative strategy, without
response adaptation, eoc-18F-FDG-PET may provide only ad-
ditional prognostic information, without any evidence in sup-
port of a change in terms of deintensification or intensification
at this step.
Some authors17 questioned the use of both i-18F-FDG-PET and
eoc-18F-FDG-PET in this patient population, as the rate of
positivity is low (around 15% among favourable and unfav-
ourable patients together); the number of lymphoma-related
Figure 1. Treatment details and outcomes according to both interim fluorine-18 fludeoxyglucose positron emission tomography and
end-of-chemotherapy fluorine-18 fludeoxyglucose positron emission tomography. ABVD, doxorubicin, bleomycin, vinblastine and
dacarbazine; ASCT, autologous stem cell transplantation; eotPET, positron emission tomography response at the end of treatment;
HL, Hodgkin lymphoma; IFRT, involved fields radiotherapy; iPET, positron emission tomography response at interim.
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deaths is small; and the use of i-18F-FDG-PET/eoc-18F-FDG-
PET would only provide a little absolute risk difference between
a large group of negative and a very small group of positive
patients in terms of OS. However, results of previous studies,5–9
as well as the present analysis, suggest a more complex scenario:
ABVD plus RT is able to cure approximately 80% of interim-
PET-positive patients, but with an unacceptable rate of disease
relapse and mortality for non-responders. eoc-18F-FDG-PET-
positive patients received higher radiation doses, however, the
potential impact of RT dose in this setting is unclear, and
unfortunately, we cannot draw any conclusion on this issue from
the present data.
Few other investigators also explored the prognostic significance
of eoc 18F-FDG-PET positivity. Sher et al11 analyzed 73 patients
with HL treated with ABVD and RT; 13 patients out of the 73
(16%) were eoc-18F-FDG-PET positive before RT. Nine of these
patients (69%) achieved a complete remission after RT, while
four (31%) relapsed. Among the PET-negative group (60 patients),
57 (97%) remained in continuous complete remission while 3
Figure 2. (a) Kaplan–Meier projections of progression-free survival, stratified by end-of-chemotherapy fluorine-18 fludeoxyglucose
positron emission tomography (eoc-18F-FDG-PET) positivity. Log-rank, p50.0001. (b) Kaplan–Meier projections of overall survival,
stratified by eoc-18F-FDG-PET positivity. Log-rank p50.0001. eocPET, positron emission tomography response at the end of
chemotherapy.
Figure 3. (a) Kaplan–Meier projections of progression-free survival, stratified by positron emission tomography (PET) response at
interim (iPET) or at the end of chemotherapy (eocPET). Log-rank p,0.0001. (b) Kaplan–Meier projections of overall survival,
stratified by fluorine-18 fludeoxyglucose (18F-FDG)-PET response during and after chemotherapy. Log-rank p50.00005.
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relapsed. All three patients who relapsed despite eoc-18F-FDG-PET
negativity obtained a continuous complete remission with a second
line therapy, and only one of four in the PET-positive group, with
a consequent inferior OS. We cannot provide data on response to
second-line chemotherapy for our cohort, but the failure rate was
significantly higher and OS projections were inferior in our study
as well.
The latter finding suggests the potential ability of eoc-18F-FDG-
PET to select patients at a worse prognosis among the cohort of
i-18F-FDG-PET positive, with a higher predictive value on PFS
of eoc-18F-FDG-PET as showed by Wilcoxon test with an in-
tegrated area under the curve of 0.685 and 0.872 for i-18F-FDG-
PET and eoc-18F-FDG-PET, respectively (p5 0.003). Besides,
despite i-18F-FDG-PET may be an attractive surrogate tool for
response, the rate of positive/negative patients (6/25, 24%) raises
significant concerns on treatment intensification at this stage.
Patients who were converted from positive into negative at the
end of treatment experienced similar outcomes as their i-18F-
FDG-PET-negative counterparts. Therefore eoc-18F-FDG-PET
may be beneficial in reducing the proportion of patients re-
ceiving intensified treatment on the basis of i-18F-FDG-PET
results, and either as a single measurement or in combination
with i-18F-FDG-PET adds important prognostic information,
being the most relevant prognostic factor at Cox regression
analysis. The recently presented results of the H10 trial (PET-
positive arms) might partially change this scenario. i-18F-FDG-
PET-positive patients who received BEACOPP-esc (escalated
cyclophosphamide, doxorubicin, etoposide, procarbazine, pred-
nisone, vincristine, bleomycin) plus RT had clearly superior
PFS rates if compared with the continuation of ABVD plus RT
(5-year PFS rate of 91% vs 77%; p5 0.002).18 This huge dif-
ference in PFS questions the continuation of ABVD plus RT in
favour of an intensified chemotherapy regimen followed by the
same RT protocol. One may argue that a proportion of these
patients could be overtreated (approximately 15% of the i-18F-
FDG-PET-positive patients, according to the present study), but
the expected global PFS is certainly higher. The information
obtained by i-18F-FDG-PET and eoc-18F-FDG-PET could be
therefore useless if the treatment strategy is unlikely to be
changed, limiting its indications to patients with unfavourable
presentations where early intensification is proposed if positive
(as for H10 PET positive). Conversely, if i-18F-FDG-PET is
planned and performed only in order to have prognostic in-
formation, the indication for a second eoc-18F-FDG-PET in the
minority of i-18F-FDG-PET-positive patients (15%) may provide
additional knowledge.
In this regard, the integration of new PET-based quantitative
methods for measuring tumour burden, as for example total
metabolic tumour volume or total lesion glycolysis,19 as well as
other clinical and biological markers, are currently being de-
veloped for a better risk stratification and personalized therapy
and will probably be used at the time of i-18F-FDG-PET response
evaluation. In conclusion, this retrospective study provides addi-
tional information on the prognostic role of i-18F-FDG-PET and
eoc-18F-FDG-PET in patients with early-stage HL treated
with combined modality therapy. On the basis of the present
data, we may suggest to use eoc 18F-FDG-PET as a strong
prognostic marker especially for patients with i-18F-FDG-PET
positivity. However, major uncertainties remain on the in-
dication, interpretation criteria and exact role of 18F-FDG-
PET in this setting. As data are accumulating and the clinical
scenario is rapidly evolving, we might need to rethink the use
of 18F-FDG-PET as a prognostic marker for early-stage HL in
the near future.
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